Rachel Kotok Goldberg Shares Developing Evidence-Based Behavioral Health Programs for Horizon Has Been a Great Career Accomplishment

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five and under with juvenile psoriatic arthritis.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a conversation with Managed Healthcare Executive recently.